On the other hand, the fifth anti-TNF-α agent, certolizumab pegol (CER), is only approved for CD by the United States Food and Drug Administration (FDA) but not by the European Medicines Agency (EMA), though it is used for PsA, RA, SpA, and psoriasis. This evidence concerns the gene TNF and rheumatoid arthritis.